试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
编号:NCT01897454登记状态:提前终止企业 / 申办者:Albert Einstein College of Medicine
药物 / 成分:Fluorouracil、Gemcitabine Hydrochloride、Intensity-Modulated Radiation Therapy、Irinotecan Hydrochloride
登记的停止原因(原文):Study was terminated due to slower than anticipated accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
Aging Mammary Stem Cells and Breast Cancer Prevention
编号:NCT02642094登记状态:提前终止企业 / 申办者:LuZhe Sun
药物 / 成分:Rapamycin
登记的停止原因(原文):The study was terminated early according to the protocol due to efficacy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
编号:NCT02649673登记状态:提前终止企业 / 申办者:SCRI Development Innovations, LLC
药物 / 成分:LCL161、Topotecan、Pegylated GCSF (PEG-GCSF)
登记的停止原因(原文):Clinical program was discontinued by Novartis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
编号:NCT02859064登记状态:提前终止企业 / 申办者:SCRI Development Innovations, LLC
药物 / 成分:Lanreotide、Y-90 microspheres
登记的停止原因(原文):Closed due to slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
编号:NCT02887248登记状态:提前终止企业 / 申办者:SCRI Development Innovations, LLC
药物 / 成分:nab-paclitaxel、Gemcitabine
登记的停止原因(原文):Enrollment issues
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
编号:NCT04209725登记状态:提前终止企业 / 申办者:SCRI Development Innovations, LLC
药物 / 成分:CPX-351、Quizartinib
登记的停止原因(原文):Closed due to slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
FLX475 in Combination With Ipilimumab in Advanced Melanoma
编号:NCT04894994登记状态:提前终止企业 / 申办者:RAPT Therapeutics, Inc., a member of the GSK plc group of companies
药物 / 成分:FLX475、Ipilimumab
登记的停止原因(原文):Change in clinical landscape
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-04
Two-Layer Method Preservation and Resuscitation of the Cadaveric Pancreas Before Transplantation
编号:NCT00592280登记状态:提前终止企业 / 申办者:University of Nebraska
药物 / 成分:Two-Layer Method pancreas preservation system drug、Two-Layer Method pancreas preservation system device
登记的停止原因(原文):Logistic problems with adequately timely organ collection and transport
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-04
Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance
编号:NCT00752479登记状态:提前终止企业 / 申办者:Mario Negri Institute for Pharmacological Research
药物 / 成分:Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil、Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil
登记的停止原因(原文):Necessity of major revision of the protocol
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-04
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
编号:NCT03458728登记状态:提前终止企业 / 申办者:Bayer
药物 / 成分:Copanlisib (BAY806946)
登记的停止原因(原文):no anticipated benefit over available standard therapies
查看官方原始记录 ↗